Form 4: Avalo Therapeutics Director Aaron Kantoff Granted 20,100 Stock Options

Avalo Therapeutics, Inc. Director Aaron Kantoff was granted 20,100 stock options with an exercise price of $4.47, vesting on June 17, 2026.

Summary

• Aaron Kantoff, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options.
• The stock options have an exercise price of $4.47 per share.
• The grant date for these options was June 17, 2025.
• The options are scheduled to vest 100% on June 17, 2026, contingent upon Mr. Kantoff's continued service as a director.
• The expiration date for these stock options is June 17, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a standard compensation practice and generally viewed as neutral to slightly positive as it aligns the director's interests with shareholder value.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

The stock options are structured to vest 100% on the first anniversary of the grant date, June 17, 2026, contingent on the director's continued service, aligning future incentives with company performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aiming to align leadership incentives with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly in the biotech sector, comparable to similar equity incentive plans at companies like BioNTech SE or Moderna, Inc., which frequently use stock-based compensation to attract and retain talent and align interests.

Related Party Transactions

• Grant of 20,100 stock options to Aaron Kantoff, a Director of Avalo Therapeutics, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for increased director alignment with long-term share price appreciation, though also potential for future dilution upon option exercise.

Next Steps

• Continued service of Aaron Kantoff as a Director until at least June 17, 2026, for the options to vest.
• Potential exercise of options by Aaron Kantoff between June 17, 2026, and June 17, 2035.

Key Dates

Keywords

Avalo Therapeutics, AVTX, stock options, director compensation, insider transaction, Form 4, beneficial ownership